Blood Cancers | Tumor

5 Factors Linked to Greater Chance of Polycythemia Vera Progression

July 23rd 2024, 3:00pm

Article

Researchers identified five traits that may increase a person’s chance of experiencing polycythemia vera progression.

Iclusig Leads to Better Responses Than Gleevec in Leukemia Subset

July 17th 2024, 3:00pm

Article

Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia had better MRD statuses after receiving Iclusig, compared with Gleevec.

Survivors May Have Successful Pregnancies After Stem Cell Transplants

July 15th 2024, 9:00pm

Article

Contrary to past research, blood cancer survivors may have safe and successful pregnancies up to 10 years after an allogeneic stem cell transplant.

My Invisible Losses That Emerge from Cancer

July 10th 2024, 5:00pm

Article

Although MDS didn’t leave physical scars, the invisible ones, like side effects from treatment, are ones that linger.

Antibody Testing May Decrease Infection Risk in Blood Cancer Survivors

July 3rd 2024, 3:00pm

Article

More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.

Some With MDS May Benefit from Delaying Stem Cell Transplants

July 1st 2024, 3:00pm

Article

For patients with MDS who benefit from delaying transplants, it’s important to take care of their health while savoring their time before transplant.

Don Omar Announces Being Cancer Free, ‘General Hospital’ Star Opens Up About Cancer and More

June 21st 2024, 3:27pm

Article

From Don Omar announcing being cancer free to “General Hospital” star John York talking about treatment for his two cancers, here’s what’s going on in the oncology space this week.

My Feeling of Survivor’s Guilt

June 19th 2024, 5:00pm

Article

As a cancer survivor, I realize that life doesn’t always go the way we think it will, but it doesn’t erase the guilt.

FDA-Approved Rytelo a ‘Game Changer’ for Some Patients with MDS

June 17th 2024, 1:00pm

Article

Approximately half of the patients with MDS who responded to treatment with Rytelo went a year without needing a blood transfusion, one expert explained.

FDA Approves Rytelo for Some With Low- to Intermediate-1-risk MDS

June 7th 2024, 1:23pm

Article

The Food and Drug Administration has approved Rytelo to treat certain patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.